ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) provided an update regarding the Company’s ongoing multicenter Phase I study of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or …
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) issued the following statement regarding the Company’s ongoing multicenter Phase 1 study of Ad-RTS-hIL-12 + orally administered veledimex in recurrent …
Ziopharm Oncology Inc (NASDAQ:ZIOP) revealed on Tuesday plans to undertake a new acute myeloid leukemia (AML) clinical trial. This trial will specifically test …
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced plans for a Phase I adoptive cellular therapy clinical …
In a research report published Friday, Griffin analyst Keith Markey reiterated a Buy rating on shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) with a price …
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced the successful completion of enrollment in the first and second …
Griffin’s healthcare analyst Keith Markey weighed in on ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), after the oncology biotech firm disclosed interim Phase 1 data for IL12 gene therapy product Ad-RTS-hIL12, …
Wells Fargo analyst Jim Birchenough maintained an Underperform rating on shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), with a valuation range of $5.
In a research report issued yesterday, Wells Fargo analyst Jim Birchenough reiterated an Underperform rating on shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), with a valuation range of $5.
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) announced financial results for the first quarter ended March 31, 2016, and provided an update on the Company’s recent activities.
